BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24411201)

  • 1. Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase (AKR1C3).
    Flanagan JU; Atwell GJ; Heinrich DM; Brooke DG; Silva S; Rigoreau LJ; Trivier E; Turnbull AP; Raynham T; Jamieson SM; Denny WA
    Bioorg Med Chem; 2014 Feb; 22(3):967-77. PubMed ID: 24411201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
    Heinrich DM; Flanagan JU; Jamieson SM; Silva S; Rigoreau LJ; Trivier E; Raynham T; Turnbull AP; Denny WA
    Eur J Med Chem; 2013 Apr; 62():738-44. PubMed ID: 23454516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3.
    Jamieson SM; Brooke DG; Heinrich D; Atwell GJ; Silva S; Hamilton EJ; Turnbull AP; Rigoreau LJ; Trivier E; Soudy C; Samlal SS; Owen PJ; Schroeder E; Raynham T; Flanagan JU; Denny WA
    J Med Chem; 2012 Sep; 55(17):7746-58. PubMed ID: 22877157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3).
    Gazvoda M; Beranič N; Turk S; Burja B; Kočevar M; Rižner TL; Gobec S; Polanc S
    Eur J Med Chem; 2013 Apr; 62():89-97. PubMed ID: 23353746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3.
    Endo S; Hu D; Matsunaga T; Otsuji Y; El-Kabbani O; Kandeel M; Ikari A; Hara A; Kitade Y; Toyooka N
    Bioorg Med Chem; 2014 Oct; 22(19):5220-33. PubMed ID: 25182963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
    Penning TM; Steckelbroeck S; Bauman DR; Miller MW; Jin Y; Peehl DM; Fung KM; Lin HK
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):182-91. PubMed ID: 16417966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
    Pippione AC; Giraudo A; Bonanni D; Carnovale IM; Marini E; Cena C; Costale A; Zonari D; Pors K; Sadiq M; Boschi D; Oliaro-Bosso S; Lolli ML
    Eur J Med Chem; 2017 Oct; 139():936-946. PubMed ID: 28881288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.
    Byrns MC; Jin Y; Penning TM
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):95-104. PubMed ID: 21087665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structures of complexes of type 5 17β-hydroxysteroid dehydrogenase with structurally diverse inhibitors: insights into the conformational changes upon inhibitor binding.
    Amano Y; Yamaguchi T; Niimi T; Sakashita H
    Acta Crystallogr D Biol Crystallogr; 2015 Apr; 71(Pt 4):918-27. PubMed ID: 25849402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3.
    Sinreih M; Sosič I; Beranič N; Turk S; Adeniji AO; Penning TM; Rižner TL; Gobec S
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5948-51. PubMed ID: 22897946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of AKR1C3 with 3-phenoxybenzoic acid bound.
    Jackson VJ; Yosaatmadja Y; Flanagan JU; Squire CJ
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2012 Apr; 68(Pt 4):409-13. PubMed ID: 22505408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor.
    Watanabe K; Kakefuda A; Yasuda M; Enjo K; Kikuchi A; Furutani T; Naritomi Y; Otsuka Y; Okada M; Ohta M
    Bioorg Med Chem; 2013 Sep; 21(17):5261-70. PubMed ID: 23845281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
    Adeniji AO; Twenter BM; Byrns MC; Jin Y; Chen M; Winkler JD; Penning TM
    J Med Chem; 2012 Mar; 55(5):2311-23. PubMed ID: 22263837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor.
    Adeniji A; Uddin MJ; Zang T; Tamae D; Wangtrakuldee P; Marnett LJ; Penning TM
    J Med Chem; 2016 Aug; 59(16):7431-44. PubMed ID: 27486833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents.
    Gobec S; Brozic P; Rizner TL
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5170-5. PubMed ID: 16183274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.
    Liedtke AJ; Adeniji AO; Chen M; Byrns MC; Jin Y; Christianson DW; Marnett LJ; Penning TM
    J Med Chem; 2013 Mar; 56(6):2429-46. PubMed ID: 23432095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
    Byrns MC; Penning TM
    Chem Biol Interact; 2009 Mar; 178(1-3):221-7. PubMed ID: 19010312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3.
    Flanagan JU; Yosaatmadja Y; Teague RM; Chai MZ; Turnbull AP; Squire CJ
    PLoS One; 2012; 7(8):e43965. PubMed ID: 22937138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3.
    Beranič N; Gobec S; Rižner TL
    Chem Biol Interact; 2011 May; 191(1-3):227-33. PubMed ID: 21182831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cinnamic acids as new inhibitors of 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3).
    Brozic P; Golob B; Gomboc N; Rizner TL; Gobec S
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):233-5. PubMed ID: 16337332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.